Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04592653
Title A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alkermes, Inc.
Indications

triple-receptor negative breast cancer

ovarian cancer

Advanced Solid Tumor

skin melanoma

colorectal cancer

renal cell carcinoma

Therapies

ALKS 4230 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.